Figure 3 . The curve of concentrations of P. nagi kernel and DPPH scavenging ability
3.4.2 Preliminary in vitro anticancer evaluation
The preliminary in vitro anticancer result ofP. nagi kernel oil against gastric cancer, breast cancer (MCF-7), lung cancer(A549) and Hela cell lines listed in table 6 . It showed that P. nagi kernel oil exhibited stronger anticancer activity against these four cancer cell lines: the anticancer efficacy against gastric cancer cell lines is in a concentration-dependent manner from 0.78125 to 25mg/mL, and the highest inhibition is 64.30%±2.80 with IC50=48.47mg/mL; the anticancer efficacy against lung cancer(A549) cell lines is in a concentration-dependent manner from 0.78125 to 50mg/mL, and the highest inhibition is 93.21%±2.24 with IC50=11.47mg/mL; the anticancer efficacy against breast cancer(MCF-7) cell lines is in a concentration-dependent manner from 0.78125 to 25mg/mL, and the highest inhibition is 52.86%±2.57 with IC50=736.14mg/mL; while the anticancer efficacy against Hela cell lines is in a concentration-dependent manner from 0.78125 to 50mg/mL, and the highest inhibition is 85.33%±3.03 with IC50=23.77mg/mL. The results imply that this oil can be also regarded as the anticancer agent.
Table 6 . Preliminary in vitro anticancer results